Canada Pension Plan Investment Board Fibrogen Inc Transaction History

Canada Pension Plan Investment Board

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2020 Nov 12, 2020	SELL	$40.47 - $45.5 $1.73 Million - $1.94 Million	-42,702 Closed	0 $0
Q2 2020 Aug 14, 2020	SELL	$32.57 - $42.83 $402,793 - $529,678	-12,367 Reduced 22.46%	42,702 $1.73 Million
Q1 2020 May 13, 2020	SELL	$23.3 - $45.96 $152,218 - $300,256	-6,533 Reduced 10.61%	55,069 $1.91 Million
Q4 2019 Feb 14, 2020	SELL	$34.58 - $48.06 $1.44 Million - $2 Million	-41,515 Reduced 40.26%	61,602 $2.64 Million
Q3 2019 Nov 12, 2019	SELL	$36.98 - $48.45 $1.27 Million - $1.67 Million	-34,477 Reduced 25.06%	103,117 $3.81 Million
Q2 2019 Aug 12, 2019	BUY	$35.13 - $55.53 $2.78 Million - $4.39 Million	79,094 Added 135.2%	137,594 $6.22 Million
Q1 2019 May 15, 2019	BUY	$42.83 - $59.91 $531,092 - $742,884	12,400 Added 26.9%	58,500 $3.18 Million
Q4 2018 Feb 06, 2019	BUY	$37.97 - $60.16 $1.75 Million - $2.77 Million	46,100 New	46,100 $2.13 Million
Q2 2018 Aug 07, 2018	SELL	$44.9 - $64.95 $2.25 Million - $3.26 Million	-50,200 Closed	0 $0
Q1 2018 May 14, 2018	BUY	$45.35 - $61.65 $2.28 Million - $3.09 Million	50,200 New	50,200 $2.32 Million

115

57.5M

2.14M

907K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $38.4M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Canada Pension Plan Investment Board, based on Form 13F filings with the SEC.

Stay updated on Canada Pension Plan Investment Board with notifications on news.